- Home
- AYRO vs RDHL Comparison
AYRO vs RDHL Comparison
Compare AYRO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- RDHL
- Stock Information
- Founded
- AYRO 2017
- RDHL 2009
- Country
- AYRO United States
- RDHL Israel
- Employees
- AYRO N/A
- RDHL N/A
- Industry
- AYRO Telecommunications Equipment
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- RDHL Health Care
- Exchange
- AYRO Nasdaq
- RDHL Nasdaq
- Market Cap
- AYRO 4.3M
- RDHL 3.8M
- IPO Year
- AYRO N/A
- RDHL N/A
- Fundamental
- Price
- AYRO $0.42
- RDHL $1.99
- Analyst Decision
- AYRO
- RDHL
- Analyst Count
- AYRO 0
- RDHL 0
- Target Price
- AYRO N/A
- RDHL N/A
- AVG Volume (30 Days)
- AYRO 340.4K
- RDHL 214.4K
- Earning Date
- AYRO 05-14-2025
- RDHL 04-10-2025
- Dividend Yield
- AYRO N/A
- RDHL N/A
- EPS Growth
- AYRO N/A
- RDHL N/A
- EPS
- AYRO N/A
- RDHL N/A
- Revenue
- AYRO $5,426.00
- RDHL $8,042,999.00
- Revenue This Year
- AYRO N/A
- RDHL $381.91
- Revenue Next Year
- AYRO N/A
- RDHL N/A
- P/E Ratio
- AYRO N/A
- RDHL N/A
- Revenue Growth
- AYRO N/A
- RDHL 23.17
- 52 Week Low
- AYRO $0.34
- RDHL $1.71
- 52 Week High
- AYRO $0.96
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- AYRO 44.44
- RDHL 51.03
- Support Level
- AYRO $0.37
- RDHL $1.82
- Resistance Level
- AYRO $0.43
- RDHL $1.93
- Average True Range (ATR)
- AYRO 0.04
- RDHL 0.08
- MACD
- AYRO 0.01
- RDHL 0.04
- Stochastic Oscillator
- AYRO 55.67
- RDHL 100.00
About AYRO AYRO Inc.
AYRO Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.